



## **General Policy Statement on Product Safety**

AmerisourceBergen® is committed to the safety of the pharmaceutical supply channel and has taken a leadership role in ensuring the security of the products it distributes.

In 2005, the Company became the first national distributor to purchase all branded, generic and over-the-counter pharmaceuticals only directly from the product's manufacturer to secure the supply channel. AmerisourceBergen believes that the next step in improving supply chain safety is electronic track and trace technology that can *track* the specific owner of a container of prescription drugs that is uniquely identified by the manufacturer and that can *trace* the chain of ownership of the container beginning with the manufacturer and ending with the current owner. The Company is investing capital and working with drug manufacturers to pilot a track and trace system in 2007.

Once received from the manufacturer, AmerisourceBergen stores the products in highly secure, temperature-controlled, modern warehouses, which are regularly audited and inspected for compliance with government standards and its own safety and security policies.

AmerisourceBergen is licensed and regulated under the authority of the Prescription Drug Marketing Act (PDMA) by each state in which it does business; and is also regulated by the Drug Enforcement Administration (DEA), which conducts regular inspections of its facilities.

In regulating distributors, the PDMA sets storage and handling requirements, specific procedures for inspecting and accepting product into inventory, and detailed record keeping relating to the receipt and disposition of prescription pharmaceuticals.

In addition, AmerisourceBergen supports federal and state legislation that would establish a uniform licensing of pharmaceutical distributors; stronger criminal penalties for those convicted of counterfeiting drugs; and uniform standards for track and trace requirements. AmerisourceBergen is committed to patient safety and continues to look for ways to further strengthen the integrity and safety of the pharmaceutical supply chain.